Focusing on Tregs as percent of CD4+ T cells, we found a 54% decrease in kidney Treg numbers in animals treated with anti–CTLA-4 or the combination compared with control, paralleling the cancer findings, and suggesting that this effect may have contributed to the efficacy of the combination treatment (Figure 5G). The gene discussed is CTLA4; the disease is cancer.